PMID- 19196143
OWN - NLM
STAT- MEDLINE
DCOM- 20090916
LR  - 20171116
IS  - 1937-335X (Electronic)
IS  - 1937-3341 (Linking)
VI  - 15
IP  - 7
DP  - 2009 Jul
TI  - In vitro characterization of immune-related properties of human fetal bone cells 
      for potential tissue engineering applications.
PG  - 1523-32
LID - 10.1089/ten.tea.2008.0222 [doi]
AB  - We describe herein some immunological properties of human fetal bone cells 
      recently tested for bone tissue-engineering applications. Adult mesenchymal stem 
      cells (MSCs) and osteoblasts were included in the study for comparison. Surface 
      markers involved in bone metabolism and immune recognition were analyzed using 
      flow cytometry before and after differentiation or treatment with cytokines. 
      Immunomodulatory properties were studied on activated peripheral blood 
      mononuclear cells (PBMCs). The immuno-profile of fetal bone cells was further 
      investigated at the gene expression level. Fetal bone cells and adult MSCs were 
      positive for Stro-1, alkaline phosphatase, CD10, CD44, CD54, and 
      beta2-microglobulin, but human leukocyte antigen (HLA)-I and CD80 were less 
      present than on adult osteoblasts. All cells were negative for HLA-II. Treatment 
      with recombinant human interferon gamma increased the presence of HLA-I in adult 
      cells much more than in fetal cells. In the presence of activated PBMCs, fetal 
      cells had antiproliferative effects, although with patterns not always comparable 
      with those of adult MSCs and osteoblasts. Because of the immunological profile, 
      and with their more-differentiated phenotype than of stem cells, fetal bone cells 
      present an interesting potential for allogeneic cell source in tissue-engineering 
      applications.
FAU - Montjovent, Marc-Olivier
AU  - Montjovent MO
AD  - Center of Translational Biomechanics, Ecole Polytechnique Federale de Lausanne, 
      Lausanne, Switzerland.
FAU - Bocelli-Tyndall, Chiara
AU  - Bocelli-Tyndall C
FAU - Scaletta, Corinne
AU  - Scaletta C
FAU - Scherberich, Arnaud
AU  - Scherberich A
FAU - Mark, Silke
AU  - Mark S
FAU - Martin, Ivan
AU  - Martin I
FAU - Applegate, Lee Ann
AU  - Applegate LA
FAU - Pioletti, Dominique P
AU  - Pioletti DP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Tissue Eng Part A
JT  - Tissue engineering. Part A
JID - 101466659
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (CD28 Antigens)
RN  - 0 (CD3 Complex)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (Histocompatibility Antigens Class II)
RN  - 0 (Immunologic Factors)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 126547-89-5 (Intercellular Adhesion Molecule-1)
RN  - 82115-62-6 (Interferon-gamma)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal/immunology
MH  - Bone and Bones/*cytology/drug effects/*immunology
MH  - CD28 Antigens/metabolism
MH  - CD3 Complex/metabolism
MH  - Cell Proliferation/drug effects
MH  - Fetus/*cytology/drug effects/*immunology
MH  - Flow Cytometry
MH  - Gene Expression Regulation/drug effects
MH  - Histocompatibility Antigens Class I/immunology
MH  - Histocompatibility Antigens Class II/immunology
MH  - Humans
MH  - Immunologic Factors/pharmacology
MH  - Intercellular Adhesion Molecule-1/immunology
MH  - Interferon-gamma/pharmacology
MH  - Leukocytes, Mononuclear/cytology/drug effects
MH  - Male
MH  - Middle Aged
MH  - Recombinant Proteins
MH  - Tissue Engineering/*methods
MH  - Tumor Necrosis Factor-alpha/pharmacology
EDAT- 2009/02/07 09:00
MHDA- 2009/09/17 06:00
CRDT- 2009/02/07 09:00
PHST- 2009/02/07 09:00 [entrez]
PHST- 2009/02/07 09:00 [pubmed]
PHST- 2009/09/17 06:00 [medline]
AID - 10.1089/ten.tea.2008.0222 [pii]
AID - 10.1089/ten.tea.2008.0222 [doi]
PST - ppublish
SO  - Tissue Eng Part A. 2009 Jul;15(7):1523-32. doi: 10.1089/ten.tea.2008.0222.